Published online Jan 16, 2024. doi: 10.12998/wjcc.v12.i2.374
Peer-review started: September 12, 2023
First decision: November 30, 2023
Revised: December 12, 2023
Accepted: December 27, 2023
Article in press: December 27, 2023
Published online: January 16, 2024
Processing time: 121 Days and 0.8 Hours
Primary central nervous system lymphoma (PCNSL) is a non-Hodgkin lymphoma that originates in the central nervous system (CNS) and is exclusively limited to the CNS. Although most PCNSLs are diffuse large B-cell lymphomas, primary CNS T-cell lymphomas (PCNSTLs) are rare. PCNSTLs typically demonstrate some degree of enhancement on contrast-enhanced magnetic resonance imaging (MRI). To the best of our knowledge, non-enhancing PCNSTL has not been reported previously.
A 69-year-old male presented to the neurology department with complaints of mild cognitive impairment and gradual onset of left lower leg weakness over a span of two weeks. Initial MRI showed asymmetric T2-hyperintense lesions within the brain. No enhancement was observed on the contrast-enhanced T1 image. The initial diagnosis was neuro-Behçet’s disease. Despite high-dose steroid therapy, no alterations in the lesions were identified on initial MRI. The patient’s symptoms deteriorated further. An MRI performed one month after the initial scan revealed an increased lesion extent. Subsequently, brain biopsy confirmed the diagnosis of PCNSTL. The patient underwent definitive combined chemo-radiotherapy. However, the patient developed bacteremia and died of septic shock approximately three months after diagnosis.
The absence of enhancement in the lesion did not rule out PCNSTL. A biopsy approach is advisable for pathological confirmation.
Core Tip: The characteristic features of primary central nervous system T-cell lymphoma (PCNSTL) are not widely recognized owing to its low incidence rate. However, most malignant tumors demonstrate enhancement on gadolinium-enhanced magnetic resonance imaging (MRI). Consequently, a lesion without enhancement on gadolinium-enhanced MRI can easily be misinterpreted, potentially underestimating its malignant potential. Given the significant differences in the management of malignant and benign lesions, an accurate diagnosis is imperative for appropriate intervention. We present a case of PCNSTL without MRI enhancement. In instances of non-enhancing lesions with a clinical suspicion of malignancy, a more aggressive diagnostic approach should be adopted.